Navigation Links
Medarex Reviews Recent Highlights and Outlook for 2009
Date:1/13/2009

ents. Statements that are not historical facts, such as statements preceded by, followed by or including the words "believe"; "expect"; "may"; "anticipate"; "projected"; "estimated"; "preliminary"; "suggest"; or "potential"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties related to product manufacturing, risks associated with the enforceability of our patents, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 The Doctors on Liens ... clients of personal injury attorneys with the best doctors working ... seen steady growth throughout their history and that trend continues ... and his team in the Tujunga / Sunland ... and massage therapist, patients can find comprehensive care and detailed ...
(Date:4/27/2015)... Sitting or standing for long periods of time can ... those whose occupation requires them to be sitting while they ... to be on their feet for most of the day, ... severe and longer lasting. These people suffer from a condition ... Northeast Houston Vein Center is offering tips on how to ...
(Date:4/27/2015)... Data Integrity Problems on the Rise: , ... Partners/Suppliers, **FDAnews Webinar**, May 19, 2015 — 1:30 p.m. ... integrity issues have become a common and ever increasing ... issues within manufacturing operations or partner networks can be ... remediating them can be even more difficult. , ...
(Date:4/27/2015)... 2015 Douglas Fitzpatrick not only ... feel secure, but also helps secure homes for animals. On ... will be manning a booth at the 2015 Fetch A ... E. 17th Ave., Columbus, Ohio. , “I am very ... feature hundreds of adoptable pets from more than forty different ...
(Date:4/27/2015)... April 27, 2015 A' Design Award ... project SMRT IMAGE Lumica by Boombang Inc Design Team ... A' Design Award in Scientific Instruments, Medical Devices and ... on SMRT IMAGE Lumica, Boombang Inc Design Team, the ... IMAGE Lumica explained “SMRT Image Lumica is a two-way ...
Breaking Medicine News(10 mins):Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2Health News:Boombang Inc Design Team wins Platinum in A' Medical Product Design Awards 2
... that a drug used to treat inflammation can have ... is an effective steroid when given with antibiotics for ... bacterial meningitis is high, especially in patients who also ... Amsterdam conducted a study to determine if treatment with ...
... Researchers observe that a new topical medication can effectively treat ... They found that in a long-term study of tazarotene cream, ... more than 55 percent// of those tested, and it continued ... ,Ultraviolet radiation from the sun is known to have ...
... Boston observe that brain imaging sheds new light on the ... stops breathing, momentarily, many times during the night.// The cause ... of the throat, causing upper airway obstruction. Sleep apnoea is ... may also be a risk factor for heart disease and ...
... observed that the first links between physiologic measurements and ... a wide range of problems such as disability, hospitalization ... than their non-frail counterparts of the same age. ... made one of the first attempts to define the ...
... recent experiments a molecule related to tetracycline can aid stop the spread ... at a new drug called COL-3,// which is related to the well-known ... upon the tissue surrounding a tumour, making that tumour less likely to ... ...
... an automobile accident causes more minor eye injuries, but reduces ... reduce the number of severe and fatal injuries. //However, the ... explored until now. ,Researchers in Virginia, USA, analysed ... They looked at the severity of the various eye injuries ...
Cached Medicine News:
(Date:4/27/2015)... , April 27, 2015 Numerous Zofran ... courts around the U.S. have highlighted serious concerns surrounding ... LLP reports. According to the U.S. Centers for ... currently on the market have enough information to determine ... of 10 expectant mothers in the U.S. take at ...
(Date:4/27/2015)... and WASHINGTON , April ... Pharmacy (NASP) and SmartBrief recently partnered to deliver a ... snapshot of the top news in the industry. The ... pharmaceutical and biotechnology manufacturers, GPOs, distributors and other specialty ... will launch on April 27, 2015. "We ...
(Date:4/27/2015)... 2015  Together with its parent partners and the ... an initiative of Morris County Prevention is Key (MCPIK), ... first-of-its-kind community effort to address the heroin/opiate crisis in ... Volunteer Parent Coaches from the ... Denise Mariano , National Council on Alcoholism and ...
Breaking Medicine Technology:Growing Zofran Birth Defects Litigation Highlights Concerns Surrounding Use of Prescription Medications During Pregnancy, According to Bernstein Liebhard LLP 2Growing Zofran Birth Defects Litigation Highlights Concerns Surrounding Use of Prescription Medications During Pregnancy, According to Bernstein Liebhard LLP 3NASP and SmartBrief Partner on Specialty Pharmacy SmartBrief 2Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 2Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 3
... June 8, 2011 Cellular Dynamics International, Inc. ... Inc ., who will distribute CDI,s iCell® Cardiomyocytes , ... cells (iPSCs), in Japan. This distribution agreement ... Dr. James Thomson and Dr. Shinya Yamanaka ...
... June 8, 2011 Reportlinker.com announces ... is available in its catalogue: ... Global Pipeline Analysis,Competitive Landscape and Market ... http://www.reportlinker.com/p0490348/Hip-Resurfacing-Implants---Global-Pipeline-AnalysisCompetitive-Landscape-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic Hip ...
Cached Medicine Technology:iPS Academia Japan, Inc. to Distribute Cellular Dynamics' iCell® Products in Japan 2iPS Academia Japan, Inc. to Distribute Cellular Dynamics' iCell® Products in Japan 3Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: